Tag - IgA nephropathy

Latest ISN Journal Editorial Selections

Kidney International® Home Dialysis:  Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference In May 2021, KDIGO held a conference on expanding home dialysis emphasizing the need for policy alignment, resources, and shared decision-making between patients, care partners, and healthcare teams to improve access and use. The conference stressed the need to advocate for...

Protecting IgA Nephropathy Patients: Sparsentan Reduces Proteinuria and Preserves Kidney Function Through to Two Years

ISN-ACT Global Trials Focus editorial team member Neeru Agarwal summarizes the design and outcomes of one of the ISN-ACT Global Trials Focus's latest trial selections. Read all global trial selections from the ISN-ACT initiative here. The "trial of the month" is available in several languages. In addition, selected clinical trials are demystified for the layperson. Efficacy and safety...

Sparsentan Decreased Proteinuria, but Failed to Slow eGFR Decline in FSGS: Data From the DUPLEX Trial – New Selection of Global Trials Out Now!

ISN-ACT Global Trials Focus Subgroup member Anastasiia Zykova summarizes the design and outcomes of the team's latest "Trial of the Month." Stay updated on the latest research and developments in kidney care: Access the new selection of global trials from the ISN-ACT initiative here. The "Trial of the Month" is available in several languages. Sparsentan Versus Irbesartan...

New! Narrated Animation on Complement System Dysregulation and Its Impact on the Kidney–Watch it Now!

The kidney is particularly susceptible to damage by complement. Activation of the complement system is tightly regulated by a series of soluble and membrane-bound proteins. Failure of these checking mechanisms is one of the major causes of complement-mediated kidney diseases. Evidence of specific complement activity has been identified in several kidney diseases, including IgA nephropathy,...

ENVISION-ing a New Way Forward in IgA Nephropathy A Phase 2 Trial of Sibeprenlimab 

Daniel O’Hara, ISN-ACT Global Trials Focus coordinator, summarizes the design and outcomes of the latest "Trial of the Month." Explore all the global trial selections for November and December here. The "Trial of the Month" is available in several languages. A Phase 2 Trial of Sibeprenlimab in Patients With IgA Nephropathy Mathur et al., N Engl J Med...

Latest ISN Journal Summaries

Kidney International®  Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification  This report proposes a two-step classification of membranous nephropathy (MN). Step one is identifying the target antigen based on a multistep algorithm. The second step is the search for a potential underlying disease or associated condition. The meeting consensus favored using an antigen-based...

ISN Journal Editorial Selections

Kidney International® Measuring Albuminuria or Proteinuria: Does One Answer Fit All?  The authors review international guideline recommendations on measuring proteinuria and albuminuria and discuss contexts where the optimal measure of proteinuria is unclear or controversial. They discuss evidence to support current recommendations for choice of measure, including the clinical settings of glomerulonephritis, transplantation, and pregnancy. They also...

“International Comparison, East vs. West”: The ISN-JSN-APSN Joint Session at the 17th International Symposium on IgA Nephropathy

The latest findings on the pathogenesis and treatment of IgAN will be presented and discussed at the 17th International Symposium on IgA Nephropathy in Tokyo, Japan, from September 27-30, 2023. The ISN, the Japanese Society of Nephrology (JSN), and the Asian Pacific Society of Nephrology (APSN) will hold a joint session, "International Comparison, East...

South Asia Regional Board Webinar: Case-based discussion and update on the management of IgA Nephropathy

IgA nephropathy is one of the most common glomerular diseases, worldwide. The diagnostic histologic hallmark is dominant or codominant IgA staining on kidney biopsy; however, patients may present with various clinical syndromes ranging from asymptomatic abnormalities noted on urinalysis, nephritic syndrome, nephrotic-nephritic syndrome to rapidly progressive glomerulonephritis with crescentic transformation. There is substantial heterogeneity in the...

Take Part in the ISN GTF Twitter Space to Discuss the TESTING Randomized Clinical Trial on Oral Methylprednisolone

  Join the ISN Global Trials Focus (GTF) editorial team and researchers from the TESTING* study for a live audio discussion on the GTF project and the TESTING randomized clinical trial on oral methylprednisolone. Access the Twitter Space conversation here on November 17, 2022, at 10 p.m. CET. Scan the QR code in the image above to...